Pearl Index Study With Low Dose Combined Oral Contraceptive

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of SH D00342A. Subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bayer
• Treatments: Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Ethinyl Estradiol-Norgestrel Combination

Criteria

Inclusion Criteria:

• Healthy women requiring contraception

Exclusion Criteria:

• Pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.